Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Moderna was recently told that the Health and Human Services Department (HHS) had withdrawn a $766million grant awarded by ...

Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since ...

Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

Under terms of the deal, Bristol Myers will pay $1.5 billion upfront, and a total of $2 billion in anniversary payments for the next few years to co-develop and co-sell BioNTech's BNT327 for the ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Cuts in NIH grants and the threat of more are discouraging investment and may drive trials out of the United States.

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer ...

We recently published a list of Jim Cramer Recently Discussed These 15 Stocks. In this article, we are going to take a look ...